Economic Burden of Intravenous Iron Products In Public Hospitals of Paris and Impact of Their New Hospital-Restricted Status.

The administration conditions of intravenous iron products (IIP) must be further supported due to safety concerns, according to a decision made by the European Commission (September 13, 2013). To achieve this European decision, French Health Authorities gave to IIP a hospital-restricted status (HRS), with two consequences on the IIP circuit: i) the dispensing of this products is now authorized by hospital pharmacies only; ii) the administration of IIP to patients must be done in a health care facility (including dialysis facilities and day care facilities). This involve that the patient must now be hospitalized to receive an intravenous iron treatment.